跳至主要内容
临床试验/JPRN-C000000385
JPRN-C000000385已完成3 期

A randomized controlled study comparing S-1 with UFT as postoperative adjuvant Chemotherapy in Rectal Cancer.

Japanese Foundation for Multidisciplinary Treatment of Cancer0 个研究点目标入组 800 人开始时间: 2006年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 1) Histologically confirmed rectal adenocarcinoma (exclude Rs)
  • 2) Histological Stage IIA, IIB, IIIA, IIIB, IIIC located
  • 3) No synchronous colorectal cancer which invade submucosa or deeper
  • 4) Curative resection with lymph node dissection
  • 5) Resection of histological curability A was performed
  • 6) No prior therapy
  • 7) Within 42 days after the operation
  • 8) Oral intake is possible
  • 9) Sufficient organ functions
  • a. WBC >= 3,500/mm3
  • b. Hemoglobin >= 9g/dL
  • c. Platelet >= 100,000/mm3
  • d. Total bilirubin <= 1.2mg/dL
  • e. AST, ALT < 100IU/L
  • f. Serum creatinine <= 1.0mg/dL
  • 10) Written informed consent

排除标准

  • 1) Anal gland derived cancer of anal canal
  • 2) Active synchronous or metachronous malignancy other than carcinoma in situ
  • 3) Serious postoperative complications
  • 4) Serious coexisting illness
  • a. interstitial pneumonia, pulmonary fibrosis
  • b. intestinal paralysis or obstruction
  • c. uncontrolled diabetes mellitus
  • d. hepatic cirrhosis
  • e. hepatic failure
  • f. renal failure
  • g. uncontrolled hypertension
  • h. history of myocardial infarction, unstable angina within 6 months prior to the registration
  • 5) Limitation of use of UFT or TS-1
  • 6) Under treatment with flucytosine, phenytoin, or warfarin
  • 7) Episode of drug allergy reaching grade 3 or more severe
  • 8) Pregnant or nursing
  • 9) Severe mental disorders
  • 10) Positive HIV
  • 11) Not suitable for participating in the study for any other reason

研究者

发起方
Japanese Foundation for Multidisciplinary Treatment of Cancer

相似试验